Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
87.11
-0.36 (-0.41%)
At close: Aug 21, 2026, 4:00 PM EDT
87.02
-0.09 (-0.10%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$941,624
Profits / Employee
-$450,007
Market Cap
12.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,346 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
ARWR News
- 5 days ago - People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Business Wire
- 17 days ago - Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 17 days ago - Arrowhead Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 17 days ago - Arrowhead Pharmaceuticals Earnings release: Q3 2026 - Filings
- 17 days ago - Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Business Wire
- 17 days ago - Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Business Wire
- 18 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire